Abstract:AbstractBackgroundWe previously examined the impact of using a cerebellar, pons, or cerebral white matter (WM) reference region (RR) on the ability of each to distinguish cortical measures of fibrillar amyloid‐(Aβ) deposition with baseline data in unimpaired presenilin (PSEN1) E280A mutation carriers and non‐carriers (NC) from the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease (API ADAD) Colombia Trial (NCT01998841). In this study, we extend our findings by comparing these RRs on their ability to distinguish longitudinal changes in cortical measures of serial Aβ‐PET scans from the completed clinical trial.MethodWe estimated template‐based (SPM12) cortical mean change using baseline, 2, and 5‐year florbetapir PET standard‐uptake value ratios (SUVRs) with three different RRs (whole cerebellum, pons, and WM) and compared carriers on placebo (placebo‐carriers, n = 82) with NC all on placebo (NC, n = 83). We calculated Cohen’s D with [95% CI] and standard deviation of NC as effect‐sizes for 2 and 5‐year cortical changes. Additionally, we characterized cerebellar Aβ burden in carriers on crenezumab (treatment‐carriers, n = 81), placebo‐carriers, and NC, using our previously reported method targeting the whole cerebellum region‐of‐interest (ROI) with pons as RR to estimate cerebellar‐to‐pons‐SUVRs and compare using a mixed‐model repeated‐measures ANOVA adjusted for age but not multiple comparisons.ResultAs expected, placebo‐carriers had significantly greater SUVR change compared with NC for all three RRs. However, the pons RR was best at detecting 2‐year changes (d = 1.75[1.39‐2.11]), and WM and pons were best at detecting 5‐year changes in cortical‐Aβ levels between placebo‐carriers and NC (pons d = 2.01[1.64‐2.39], WM d = 2.51[2.10‐2.92]). Additionally, treatment‐carriers had higher cerebellar‐to‐pons‐SUVRs compared with placebo‐carriers at baseline and 2‐years, but not 5‐years (p = .034, p = .027,& p = .06,respectively), both carrier groups had higher cerebellar‐to‐pons‐SUVRs compared to NC at each interval(p2‐year>baseline,p.05).ConclusionUse of pons for 2‐year and WM or pons RRs for 5‐year changes may improve the power to track longitudinal increases and evaluate Aβ‐modifying treatments in 2 and 5‐year studies, in this ADAD population. A cerebellar RR may be confounded by early Aβ deposition in the cerebellum which can artificially reduce average cortical Aβ‐PET SUVRs even in preclinical stages of ADAD.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

P4‐298: IMPROVING THE POWER TO TRACK FIBRILLAR AMYLOID PET MEASUREMENTS AND EVALUATE AMYLOID‐MODIFYING TREATMENTS USING A CEREBRAL WHITE MATTER REFERENCE REGION‐OF‐INTEREST

Impact of Different PET Image Quantification Methods, Regions-of-interest and Risk Factors on the Power to Detect a Slowing in Beta-Amyloid Deposition in Presymptomatic Alzheimer's Disease Trials

Investigation of the Impact of the H310A FcRn Region Mutation on 89Zr-Immuno-PET Brain Imaging with a BBB-Shuttle Anti‑Amyloid Beta Antibody

Amyloid‐β PET in Alzheimer's Disease: A Systematic Review and Bayesian Meta‐analysis

Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease

Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.

Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.

P3‐299: Chronic Administration of a Novel BACE Inhibitor Reduced Brain Aβ Levels and Mature Plaques and Modestly Improved Cognition in Transgenic CRND8‐APPswe/ind Mice

PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers

Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers

SCIDOT-39. K16ApoE ENHANCES Aβ-ASSOCIATED 11C-PiB DEPOSITION AND PET SIGNAL IN APP/PS1 TRANSGENIC MICE

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact

Quantitative Amyloid Imaging In Autosomal Dominant Alzheimer'S Disease: Results From The Dian Study Group

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

O3‐02‐02: AMYLOID PET, TAU PET, AND MRI MEASUREMENTS IN COGNITIVELY UNIMPAIRED PERSONS WITH TWO, ONE, AND NO COPIES OF THE APOE4 ALLELE

Impact of Reference Region on Longitudinal Florbetapir PET SUVR Changes from the API ADAD Colombia Trial

Pre-Symptomatic Functional Brain Changes in Ps1 E280a Mutation Carriers Compared to Other Biomarkers: Pilot Data from the Alzheimer'S Prevention Initiative Biomarker Project

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease

Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer's Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers